Owkin, Genmab A/S to explore cancer patient profiles for treatment improvements
Today, Owkin announced a research agreement with Genmab A/S (Nasdaq: GMAB), an international biotechnology company specializing in the creation and development of differentiated antibody therapeutics to fight against cancer and other serious diseases, to better understand the complex biological profiles of cancer patients.
Owkin will apply state-of-the-art machine learning to multimodal patient data, accessed through their federated research network of leading academic centers and medical experts to improve patient outcomes by analysing certain patient subgroups’ response to treatments in an effort to evaluate the medical impact of Genmab’s clinical assets, including trial design and patient selection.
The research agreement will focus on patients diagnosed with certain types of cancers.
Financial terms are not disclosed but include an upfront payment and R&D funding.
About Owkin
Owkin is an agentic AI company on a mission to explore complex biology to speed up and scale research for the creation of new treatments and diagnostics for patients. Owkin K, our AI co-pilot combines unparalleled access to multimodal data, cutting-edge AI to quantify biology and pioneering agentic AI to achieve Biological Artificial Superintelligence in the future.